Results 231 to 240 of about 189,176 (292)

Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomised, double-blind, parallel-group, placebo-controlled trial. [PDF]

open access: yesEur Respir J
Diab N   +16 more
europepmc   +1 more source

Symptom cluster profiles in adolescents with inflammatory bowel disease: Cross‐sectional study using ImproveCareNow data

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Sleep disturbance, pain, anxiety, depression, and fatigue are prevalent in adolescents and young adults with inflammatory bowel disease (IBD). These symptoms often present in co‐occurring sets, known as symptom clusters. We aimed to identify distinct symptom clusters and factors associated with symptom profiles in adolescents with ...
Caeli Malloy   +6 more
wiley   +1 more source

Antibiotics in the first week of life are not associated with functional gastrointestinal disorders at 9–12 years of age

open access: yesJournal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Dysbiosis due to early‐life antibiotics may contribute to the development of functional gastrointestinal disorders (FGIDs). This follow‐up study of a birth cohort primarily investigates the association between antibiotic treatment in the first week of life and the presence of FGIDs at 9–12 years.
Nora C. Carpay   +3 more
wiley   +1 more source

Six-Month Benralizumab Maintenance for Relapsing Chronic Eosinophilic Pneumonia Guided by Eosinophil Kinetics. [PDF]

open access: yesRespirol Case Rep
Sumi T   +6 more
europepmc   +1 more source

Gastrointestinal strictures in a pediatric patient with Satoyoshi syndrome

open access: yesJPGN Reports, EarlyView.
Abstract We present a novel case of gastrointestinal strictures in a young girl with Satoyoshi syndrome (SS), highlighting multi‐system features of alopecia universalis, painful muscle cramps with dystonia, aberrant growth velocity, and skeletal abnormalities.
Katherine (Tusia) Pohoreski   +5 more
wiley   +1 more source

Depemokimab and the twice-yearly regimen: pharmacological implications and therapeutic positioning in severe eosinophilic respiratory diseases. [PDF]

open access: yesFront Immunol
Marra AM   +15 more
europepmc   +1 more source

Dupilumab as an effective therapy for eosinophilic esophagitis in pediatric patients weighing less than 15 kilograms

open access: yesJPGN Reports, EarlyView.
Abstract Objectives Eosinophilic esophagitis (EoE) is a type 2 cytokine‐mediated chronic inflammatory condition leading to esophageal dysfunction. Dupilumab blocks IL‐4 and IL‐13 signaling, which are key inflammatory mediators in EoE and other allergic disorders.
Sindhura Kasturi   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy